rpmjResearch'n Practical Medicine JournalResearch and Practical Medicine Journal2410-1893"QUASAR", LLC10.17709/2410-1893-2025-12-3-7YARILLrpmj-1136Research ArticleОбзорыReviewВозможности применения вакцинотерапии для лечения глиобластомPossibilities of vaccine therapy for the treatment of glioblastomahttps://orcid.org/0000-0001-6265-8500ГорошинскаяИ. А.GoroshinskayaI. A.

 

Горошинская Ирина Александровна – д.б.н., профессор, старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: https://orcid.org/0000-0001-6265-8500

eLibrary SPIN: 9070-4855, Author ID: 79968

Scopus Author ID: 6602191458

WoS Researcher ID: Y-2277-2018

 

Irina A. Goroshinskaya – Dr. Sci. (Biology), Professor, Senior Researcher of the Laboratory of Malignant Tumor Pathogenesis Study, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0001-6265-8500

eLibrary SPIN: 9070-4855, Author ID: 79968

Scopus Author ID: 6602191458

WoS Researcher ID: Y-2277-2018

iagor17@mail.ruhttps://orcid.org/0000-0003-3618-6890ФранциянцЕ. М.FrantsiyantsE. M.

 

Франциянц Елена Михайловна – д.б.н., профессор, заместитель генерального директора по науке ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: http://orcid.org/0000-0003-3618-6890

eLibrary SPIN: 9427-9928, Author ID: 462868

Scopus Author ID: 55890047700

WoS ResearcherID: Y-1491-2018

 

Elena M. Frantsiyants – Dr. Sci. (Biology), Professor, Deputy General Director for Science, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: http://orcid.org/0000-0003-3618-6890

eLibrary SPIN: 9427-9928, Author ID: 462868

Scopus Author ID: 55890047700

WoS ResearcherID: Y-1491-2018

super.gormon@yandex.ruhttps://orcid.org/0000-0002-3972-2452КаплиеваИ. В.KaplievaI. V.

 

Каплиева Ирина Викторовна – д.м.н., доцент, заведующая лабораторией изучения патогенеза злокачественных опухолей ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCI: http://orcid.org/0000-0002-3972-2452

eLibrary SPIN: 5047-1541, Author ID: 734116

Scopus Author ID: 23994000800

WoS ResearcherID: ААЕ-3540-2019

 

Irina V. Kaplieva – Dr. Sci. (Medicine), Associate Professor, Head of the Laboratory of Malignant Tumor Pathogenesis Study, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCI: http://orcid.org/0000-0002-3972-2452

eLibrary SPIN: 5047-1541, Author ID: 734116

Scopus Author ID: 23994000800

WoS ResearcherID: ААЕ-3540-2019

kaplirina@yandex.ruhttps://orcid.org/0000-0002-4318-7587СуриковаЕ. И.SurikovaE. I.

 

Сурикова Екатерина Игоревна – к.б.н., старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: https://orcid.org/0000-0002-4318-7587

eLibrary SPIN: 2401-4115, Author ID: 301537

Scopus Author ID: 6507092816

WoS ResearcherID: AAG-8748-2019

 

Ekaterina I. Surikova – Cand. Sci. (Biology), Senior Researcher of the Laboratory of Malignant Tumor Pathogenesis Study, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0002-4318-7587

eLibrary SPIN: 2401-4115, Author ID: 301537

Scopus Author ID: 6507092816

WoS ResearcherID: AAG-8748-2019

sunsur2000@mail.ruhttps://orcid.org/0000-0002-2302-8271БандовкинаВ. А.BandovkinaV. A.

 

Бандовкина Валерия Ахтямовна – д.б.н., доцент, ведущий научный сотрудник лаборатории изучения патогенеза злокачественных опухолей ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: https://orcid.org/0000-0002-2302-8271

eLibrary SPIN: 8806-2641, Author ID: 696989

Scopus Author ID: 57194276288

WoS ResearcherID: AAG-8708-2019

 

Valerija A. Bandovkina – Dr. Sci. (Biology), Associate Professor, Leading Researcher at Laboratory of Malignant Tumor Pathogenesis Study, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0002-2302-8271

eLibrary SPIN: 8806-2641, Author ID: 696989

Scopus Author ID: 57194276288

WoS ResearcherID: AAG-8708-2019

valerryana@yandex.ruhttps://orcid.org/0000-0002-0068-0881УшаковаН. Д.UshakovaN. D.

 

Ушакова Наталья Дмитриевна – д.м.н., профессор, врач анестезиолог-реаниматолог отделения анестезиологии реанимации ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: https://orcid.org/0000-0002-0068-0881

eLibrary SPIN: 9715-2250, Author ID: 571594

Scopus Author ID: 8210961900

 

Nataliya D. Ushakova – Dr. Sci. (Medicine), MD, Professor, anesthesiologist-resuscitator of the Department of Anesthesiology and Resuscitation, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0002-0068-0881

eLibrary SPIN: 9715-2250, Author ID: 571594

Scopus Author ID: 8210961900

ndu2000@rambler.ruhttps://orcid.org/0000-0002-4558-5896ФилипповаС. Ю.FilippovaS. Yu.

 

Филиппова Светлана Юрьевна – научный сотрудник лаборатории клеточных технологий опухолей ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: https://orcid.org/0000-0002-4558-5896

eLibrary SPIN: 9586-2785, Author ID: 878784

Scopus Author ID: 57189618843

WoS ResearcherID: AAH-4408-2020

 

Svetlana Yu. Filippova – research fellow at the laboratory of cell technologies, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0002-4558-5896

eLibrary SPIN: 9586-2785, Author ID: 878784

Scopus Author ID: 57189618843

WoS ResearcherID: AAH-4408-2020

filsv@yandex.ruhttps://orcid.org/0000-0002-7902-7278МежевоваИ. В.MezhevovaI. V.

 

Межевова Ирина Валентиновна – младший научный сотрудник лаборатории клеточных технологий опухолей ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: https://orcid.org/0000-0002-7902-7278

eLibrary SPIN: 3367-1741, Author ID: 1011695

Scopus Author ID: 57296602900

WoS ResearcherID: AAI-1860-2019

 

Irina V. Mezhevova – junior research fellow at the laboratory of cell technologies, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0002-7902-7278

eLibrary SPIN: 3367-1741, Author ID: 1011695

Scopus Author ID: 57296602900

WoS ResearcherID: AAI-1860-2019

mezhevova88@gmail.comhttps://orcid.org/0000-0003-2937-0470РосторгуевЭ. Е.RostorguevE. E.

 

Росторгуев Эдуард Евгеньевич – д.м.н., доцент, врач-нейрохирург, заведующий отделением нейроонкологии ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: https://orcid.org/0000-0003-2937-0470

eLibrary SPIN: 8487-9157, AuthorID: 794808

Scopus Author ID: 57196005138

WoS ResearcherID: AAK-6852-2020

 

Eduard E. Rostorguev – Dr. Sci. (Medicine), MD, Associate Professor, neurosurgeon, Head of the Department of Neurooncology, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0003-2937-0470

eLibrary SPIN: 8487-9157, AuthorID: 794808

Scopus Author ID: 57196005138

WoS ResearcherID: AAK-6852-2020

ed.rost@mail.ruhttps://orcid.org/0000-0002-2337-326XКузнецоваН. С.KuznetsovaN. S.

 

Кузнецова Наталья Сергеевна – врач-онколог отделения нейроонкологии ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: https://orcid.org/0000-0002-2337-326X

eLibrary SPIN: 8553-3081, AuthorID: 920734

Scopus Author ID: 57208052623

WoS ResearcherID: AAG-8960-2020

 

Natalia S. Kuznetsova – MD, oncologist, Department of Neurooncology, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0002-2337-326X

eLibrary SPIN: 8553-3081, AuthorID: 920734

Scopus Author ID: 57208052623

WoS ResearcherID: AAG-8960-2020

Kyznet.nat@gmail.comhttps://orcid.org/0000-0002-6924-8974КавицкийС. Э.KavitskiyS. E.

 

Кавицкий Сергей Эммануилович – к.м.н., врач-нейрохирург консультативно-диагностического отделения ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация

ORCID: https://orcid.org/0000-0002-6924-8974

eLibrary SPIN: 6437-0420, AuthorID: 734582

 

Sergey E. Kavitskiy – Cand. Sci. (Medicine), MD, neurosurgeon, Consulting and Diagnostic Department, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0002-6924-8974

eLibrary SPIN: 6437-0420, AuthorID: 734582

kavser@yandex.ruНациональный медицинский исследовательский центр онкологии Министерства здравоохранения Российской Федерации <p> г. Ростов-на-Дону, Российская ФедерацияNational Medical Research Centre for Oncology <p> Rostov-on-Don, Russian Federation2025090920251237186Copyright &#x00A9; Горошинская И.А., Франциянц Е.М., Каплиева И.В., Сурикова Е.И., Бандовкина В.А., Ушакова Н.Д., Филиппова С.Ю., Межевова И.В., Росторгуев Э.Е., Кузнецова Н.С., Кавицкий С.Э., 20252025Горошинская И.А., Франциянц Е.М., Каплиева И.В., Сурикова Е.И., Бандовкина В.А., Ушакова Н.Д., Филиппова С.Ю., Межевова И.В., Росторгуев Э.Е., Кузнецова Н.С., Кавицкий С.Э.Goroshinskaya I.A., Frantsiyants E.M., Kaplieva I.V., Surikova E.I., Bandovkina V.A., Ushakova N.D., Filippova S.Y., Mezhevova I.V., Rostorguev E.E., Kuznetsova N.S., Kavitskiy S.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpmj.ru/rpmj/article/view/1136

Глиобластома является самой распространенной и наиболее агрессивной первичной опухолью головного мозга со средней выживаемостью менее двух лет. Большие надежды в комплексном лечении глиобластом возлагаются на использование иммунотерапии, в том числе вакцинотерпии.Цель исследования. На основании анализа современных научных публикаций отразить особенности применения вакцинотерапии при опухолях головного мозга и представить результаты, полученные в России и за рубежом.Материалы и методы. Поиск литературы производился в системах Medline, E-library, PubMed. Результаты. В обзоре представлены данные о неудовлетворительных результатах стандартного лечения глиобластом, охарактеризованы их биологические отличия, определяющие слабую чувствительность к большинству видов противоопухолевой терапии и сложности, возникающие при вакцинации; описаны свойства дендритных клеток (ДК) и их значимость для разработки одного из основных типов вакцин. Освещены результаты нерандомизированных и немногочисленных рандомизированных исследований по клиническому использованию в России и за рубежом вакцинотерапии, главным образом дендритно-­ клеточных вакцин (ДКВ) у больных с глиобластомами. Подчеркнута перспективность персонифицированной вакцинации, описано влияние ДКВ на компоненты иммунной системы, а также двоякая роль экзосом в развитии злокачественного процесса, устойчивости к лечению и возможности их использования при создании вакцин. Представлены сведения о клиническом опыте применения пептидных вакцин и вакцин на основе матричной РНК.Заключение. Несмотря на определенные сложности применения вакцинотерапии у больных глиобластомами, в России и за рубежом получены обнадеживающие результаты. Противоопухолевые вакцины обладают несомненным потенциалом для лечения глиобластом и становятся перспективными методами иммунотерапии, которые могут принести клиническую пользу пациентам с этими наиболее агрессивными и трудно поддающимися терапии злокачественными опухолями.

Glioblastoma is the most common and most aggressive primary brain tumor with a median survival of less than two years. Great hopes in the complex treatment of glioblastomas are placed on the use of immunotherapy, including vaccine therapy.Purpose of the study. To reflect the features of the use of vaccine therapy for brain tumors based on the analysis of modern scientific publications and present the results obtained in Russia and abroad. Materials and methods. The literature search was conducted in the Medline, E-library, PubMed systems.Results. The review presents data on unsatisfactory results of standard treatment of glioblastomas, characterizes their biological differences that determine weak sensitivity to most types of antitumor therapy and difficulties arising during vaccination; describes the properties of dendritic cells and their significance for the development of one of the main types of vaccines. The results of non-randomized and few randomized studies on the clinical use of vaccine therapy in Russia and abroad, mainly dendritic cell vaccines (DCVs) in patients with glioblastomas are highlighted. The prospects of personalized vaccination are emphasized; the effect of DCVs on some components of the immune system is described, as well as the dual role of exosomes in the development of a malignant process, resistance to treatment and the possibility of their use in creating vaccines. Information on clinical experience with the use of peptide vaccines and vaccines based on matrix RNA is presented.Conclusion. Despite certain difficulties in the use of vaccine therapy in patients with glioblastomas, encouraging results have been obtained in Russia and abroad. It is emphasized that antitumor vaccines have undoubted potential for the treatment of glioblastomas and are becoming promising methods of immunotherapy that can bring clinical benefit to patients with these most aggressive and difficult to treat malignant tumors.

опухоли головного мозгаглиобластомыдендритные клеткииммунотерапиявакциныbrain tumorsglioblastomadendritic cellsimmunotherapyvaccinesReferencesЗлокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. 276 с. Доступно по: https://oncology-association.ru/wp-content/uploads/2024/08/zis-2023-elektronnaya-versiya.pdf. Дата обращения 21.02.2025.Malignant neoplasms in Russia in 2023 (morbidity and mortality). Edited by Kaprin AD, Starinsky VV, Shakhzadova AO. Мoscow: P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation, 2024, 276 p. (In Russ.) Available at: https://oncology-association.ru/wp-content/uploads/2024/08/zis-2023-elektronnaya-versiya.pdf Accessed 21.02.2025.Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025 Jan-Feb;75(1):10–45. https://doi.org/10.3322/caac.21871Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025 Jan-Feb;75(1):10–45. https://doi.org/10.3322/caac.21871Яковленко Ю.Г. Глиобластомы: современное состояние проблемы. Медицинский вестник Юга России. 2019;10(4):28–35. https://doi.org/10.21886/2219-8075-2019-10-4-28-35Yakovlenko YG. Glioblastoma: the current state of the problem. Medical Herald of the South of Russia. 2019;10(4):28–35. (In Russ.). https://doi.org/10.21886/2219-8075-2019-10-4-28-35Van Gool SW, Makalowski J, Kampers LFC, Van de Vliet P, Sprenger T, Schirrmacher V, Stücker W. Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached? Transl Cancer Res. 2023 Aug 31;12(8):2224–2228. https://doi.org/10.21037/tcr-23-603Van Gool SW, Makalowski J, Kampers LFC, Van de Vliet P, Sprenger T, Schirrmacher V, Stücker W. Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached? Transl Cancer Res. 2023 Aug 31;12(8):2224–2228. https://doi.org/10.21037/tcr-23-603Kurokawa R, Kurokawa M, Baba A, Ota Y, Pinarbasi E, Camelo-Piragua S, et al. Major changes in 2021 World Health Organization classification of central nervous system tumors. Radiographics. 2022 Sep-Oct;42(5):1474–1493. https://doi.org/10.1148/rg.210236Kurokawa R, Kurokawa M, Baba A, Ota Y, Pinarbasi E, Camelo-Piragua S, et al. Major changes in 2021 World Health Organization classification of central nervous system tumors. Radiographics. 2022 Sep-Oct;42(5):1474–1493. https://doi.org/10.1148/rg.210236Митрофанов А.А., Насхлеташвили Д.Р., Алешин В.А., Белов Д.М., Бекяшев А.Х., Карахан В.Б. и др. Причины лекарственной устойчивости и рецидивов глиобластом. Опухоли головы и шеи. 2021;11(1):101–108. https://doi.org/10.17650/2222 1468 2021 11 1 101 108Mitrofanov AA, Naskhletashvili DR, Aleshin VA, Belov DM, Bekyashev AKh, Karakhan VB, et al. Causes of drug resistance and glioblastoma relapses. Head and Neck Tumors (HNT). 2021;11(1):101–108. (In Russ.). https://doi.org/10.17650/2222 1468 2021 11 1 101 108Datsi A, Sorg RV. Dendritic cell vaccination of glioblastoma: Road to success or dead end. Front Immunol. 2021 Nov 2;12:770390. https://doi.org/10.3389/fimmu.2021.770390Datsi A, Sorg RV. Dendritic cell vaccination of glioblastoma: Road to success or dead end. Front Immunol. 2021 Nov 2;12:770390. https://doi.org/10.3389/fimmu.2021.770390Vanderbeek AM, Rahman R, Fell G, Ventz S., Chen T., Redd R. et al. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro Oncol. 2018;20(8):1034–1043. https://doi.org/10.1093/neuonc/noy027Vanderbeek AM, Rahman R, Fell G, Ventz S., Chen T., Redd R. et al. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro Oncol. 2018;20(8):1034–1043. https://doi.org/10.1093/neuonc/noy027Stupp R, Taillibert S, Kanner A, Read W., Steinberg DM., Lhermitte B. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306–2316. https://doi.org/10.1001/jama.2017.18718Stupp R, Taillibert S, Kanner A, Read W., Steinberg DM., Lhermitte B. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306–2316. https://doi.org/10.1001/jama.2017.18718Тишина А.В., Владимирова Л.Ю., Сагакянц А.Б., Дженкова Е.А., Новикова И.А., Златник Е.Ю. Иммунологические аспекты прогрессирования колоректального рака. Южно-Российский онкологический журнал. 2024;5(1):52–59. https://doi.org/10.37748/2686-9039-2024-5-1-6Tishina AV, Vladimirova LYu, Sagakyants AB, Dzhenkova EA, Novikova IA, Zlatnik EYu. Immunologic aspects of colorectal cancer progression. South Russian Journal of Cancer. 2024;5(1):52–59. https://doi.org/10.37748/2686-9039-2024-5-1-6Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. https://doi.org/10.1056/NEJMoa1504030.Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. https://doi.org/10.1056/NEJMoa1504030.Buerki RA, Chheda ZS, Okada H. Immunotherapy of primary brain tumors: facts and hopes. Clin Cancer Res. 2018;24(21):5198– 5205. https://doi.org/10.1158/1078-0432.CCR-17-2769Buerki RA, Chheda ZS, Okada H. Immunotherapy of primary brain tumors: facts and hopes. Clin Cancer Res. 2018;24(21):5198– 5205. https://doi.org/10.1158/1078-0432.CCR-17-2769Hotchkiss KM, Batich KA, Mohan A, Rahman R, Piantadosi S, Khasraw M. Dendritic cell vaccine trials in gliomas: Untangling the lines. Neuro Oncol. 2023 Oct 3;25(10):1752–1762. https://doi.org/10.1093/neuonc/noad088Hotchkiss KM, Batich KA, Mohan A, Rahman R, Piantadosi S, Khasraw M. Dendritic cell vaccine trials in gliomas: Untangling the lines. Neuro Oncol. 2023 Oct 3;25(10):1752–1762. https://doi.org/10.1093/neuonc/noad088Chistiakov DA, Chekhonin VP. Circulating tumor cells and their advances to promote cancer metastasis and relapse, with focus on glioblastoma multiforme. Exp Mol Pathol. 2018;105(2):166–174. https://doi.org/10.1016/j.yexmp.2018.07.007Chistiakov DA, Chekhonin VP. Circulating tumor cells and their advances to promote cancer metastasis and relapse, with focus on glioblastoma multiforme. Exp Mol Pathol. 2018;105(2):166–174. https://doi.org/10.1016/j.yexmp.2018.07.007Wei J, Chen P, Gupta P, Ott M, Zamler D, Kassab C, et al. Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. Neuro Oncol. 2020 Feb 20;22(2):180–194. https://doi.org/10.1093/neuonc/noz212Wei J, Chen P, Gupta P, Ott M, Zamler D, Kassab C, et al. Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. Neuro Oncol. 2020 Feb 20;22(2):180–194. https://doi.org/10.1093/neuonc/noz212Reardon DA, Mitchell DA. The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Semin Immunopathol. 2017;39(2):225–239. https://doi.org/10.1007/s00281-016-0616-7Reardon DA, Mitchell DA. The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Semin Immunopathol. 2017;39(2):225–239. https://doi.org/10.1007/s00281-016-0616-7Yan Y, Zeng S, Gong Z, Xu Z. Clinical implication of cellular vaccine in glioma: current advances and future prospects. J Exp Clin Cancer Res. 2020 Nov 23;39(1):257. https://doi.org/10.1186/s13046-020-01778-6Yan Y, Zeng S, Gong Z, Xu Z. Clinical implication of cellular vaccine in glioma: current advances and future prospects. J Exp Clin Cancer Res. 2020 Nov 23;39(1):257. https://doi.org/10.1186/s13046-020-01778-6Marciscano AE, Anandasabapathy N. The role of dendritic cells in cancer and anti-tumor immunity. Semin Immunol. 2021Feb;52:101481. https://doi.org/10.1016/j.smim.2021.101481Marciscano AE, Anandasabapathy N. The role of dendritic cells in cancer and anti-tumor immunity. Semin Immunol. 2021Feb;52:101481. https://doi.org/10.1016/j.smim.2021.101481Wang Y, Xiang Y, Xin VW, Wang XW, Peng XC, Liu XQ, et al. Dendritic Cell Biology and its Role in Tumor Immunotherapy. J Hematol Oncol. 2020;13:107. https://doi.org/10.1186/s13045-020-00939-6Wang Y, Xiang Y, Xin VW, Wang XW, Peng XC, Liu XQ, et al. Dendritic Cell Biology and its Role in Tumor Immunotherapy. J Hematol Oncol. 2020;13:107. https://doi.org/10.1186/s13045-020-00939-6Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic Cells in Cancer Immunology and Immunotherapy. Nat Rev Immunol. 2020;20:7–24. https://doi.org/10.1038/s41577-019-0210-zWculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic Cells in Cancer Immunology and Immunotherapy. Nat Rev Immunol. 2020;20:7–24. https://doi.org/10.1038/s41577-019-0210-zZhou J, Li L, Jia M, Liao Q, Peng G, Luo G, Zhou Y. Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions. Cancer Med. 2023 Mar;12(6):7207–7221. https://doi.org/10.1002/cam4.5511Zhou J, Li L, Jia M, Liao Q, Peng G, Luo G, Zhou Y. Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions. Cancer Med. 2023 Mar;12(6):7207–7221. https://doi.org/10.1002/cam4.5511Böttcher JP, Reis e Sousa C. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer. 2018;4(11):784–792. https://doi.org/10.1016/j.trecan.2018.09.001Böttcher JP, Reis e Sousa C. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer. 2018;4(11):784–792. https://doi.org/10.1016/j.trecan.2018.09.001Zheng Y, Ma X, Feng S, Zhu H, Chen X, Yu X, Shu K and Zhang S. Dendritic cell vaccine of gliomas: challenges from bench to bed. Front Immunol. 2023;14:1259562. https://doi.org/10.3389/fimmu.2023.1259562Zheng Y, Ma X, Feng S, Zhu H, Chen X, Yu X, Shu K and Zhang S. Dendritic cell vaccine of gliomas: challenges from bench to bed. Front Immunol. 2023;14:1259562. https://doi.org/10.3389/fimmu.2023.1259562Mitchell D, Chintala S, Dey M. Plasmacytoid dendritic cell in immunity and cancer. J Neuroimmunol. 2018;322:63–73. https://doi.org/10.1016/j.jneuroim.2018.06.012Mitchell D, Chintala S, Dey M. Plasmacytoid dendritic cell in immunity and cancer. J Neuroimmunol. 2018;322:63–73. https://doi.org/10.1016/j.jneuroim.2018.06.012De Martino M, Vanpouille-Box C. Type I interferon induces cancer stem cells mediated chemotherapy resistance. Oncoimmunology. 2022;11(1):2127274. https://doi.org/10.1080/2162402X.2022.2127274De Martino M, Vanpouille-Box C. Type I interferon induces cancer stem cells mediated chemotherapy resistance. Oncoimmunology. 2022;11(1):2127274. https://doi.org/10.1080/2162402X.2022.2127274Рыков М.Ю., Долгополов И.С. Опыт применения дендритных вакцин в лечении пациентов с рецидивными глиомами. Исследования и практика в медицине. 2022;9(4):18–29. https://doi.org/10.17709/2410-1893-2022-9-4-2Rykov MYu, Dolgopolov IS. Experience in the use of dendritic vaccines in the treatment of patients with recurrent gliomas. Research and Practical Medicine Journal. 2022;9(4):18–29. (In Russ.). https://doi.org/10.17709/2410-1893-2022-9-4-2Pellegatta S, Eoli M, Cuccarini V, Anghileri E, Pollo B, Pessina S, et al. Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide. Oncoimmunology. 2018 Jan 29;7(4):e1412901. https://doi.org/10.1080/2162402X.2017.1412901Pellegatta S, Eoli M, Cuccarini V, Anghileri E, Pollo B, Pessina S, et al. Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide. Oncoimmunology. 2018 Jan 29;7(4):e1412901. https://doi.org/10.1080/2162402X.2017.1412901Eoli M, Corbetta C, Anghileri E, Di Ianni N, Milani M, Cuccarini V, et al. Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy. Neurooncol Adv. 2019 Aug 20;1(1):vdz022. https://doi.org/10.1093/noajnl/vdz022Eoli M, Corbetta C, Anghileri E, Di Ianni N, Milani M, Cuccarini V, et al. Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy. Neurooncol Adv. 2019 Aug 20;1(1):vdz022. https://doi.org/10.1093/noajnl/vdz022Litterman AJ, Zellmer DM, Grinnen KL, Hunt MA, Dudek AZ, Salazar AM, Ohlfest JR. Profound impairment of adaptive immune responses by alkylating chemotherapy. The Journal of Immunology. 2013;190(12):6259–6268. https://doi.org/10.4049/jimmunol.1203539Litterman AJ, Zellmer DM, Grinnen KL, Hunt MA, Dudek AZ, Salazar AM, Ohlfest JR. Profound impairment of adaptive immune responses by alkylating chemotherapy. The Journal of Immunology. 2013;190(12):6259–6268. https://doi.org/10.4049/jimmunol.1203539Балдуева И.А., Беляев А.М. Вехи развития онкоиммунологии в НМИЦ онкологии им. Н.Н. Петрова Исторический очерк к 110-летию со дня рождения профессора Тамары Александровны Коростелёвой (1913−1991). Вопросы онкологии. 2023;69(5):949–959. https://doi.org/10.37469/0507-3758-2023-69-5-949-959Baldueva IA, Beliaev AM. Milestones in the development of oncoimmunology at the N.N. Petrov NMRC of oncology historical essay on the 110th anniversary of professor Tamara Aleksandrovna Korosteleva (1913-1991). Problems in Oncology. 2023;69(5):949–959. (In Russ.). https://doi.org/10.37469/0507-3758-2023-69-5-949-959Балдуева И.А., Новик А.В., Ефремова Н.А., Нехаева Т.Л., Данилова А.Б., Емельянова Н.В., и др. Эффективность лечения первичных опухолей центральной нервной системы аутологичной дендритно-клеточной вакциной CATEVAC. Вопросы онкологии. 2022;68(3S):158–159.Baldueva IA, Novik AV, Efremova NA, Nekhaeva TL, Danilova AB, Emel'yanova NV, et al. The effectiveness of treatment of primary tumors of the central nervous system with the autologous CATEVAC dendritic cell vaccine. Problems in Oncology. 2022;68(3S):158– 159. (In Russ.).Кулева С.А., Борокшинова К.М., Балдуева И.А., Нехаева Т.Л., Артемьева А.С., Ефремова Н.А., и др. Опыт использования мультитаргетной противоопухолевой вакцины у ребенка с диффузной срединной глиомой головного мозга с альтерацией в гене H3 K27. Вопросы онкологии. 2023;69(3):555–564. https://doi.org/10.37469/0507-3758-2023-69-3-555-564Kulyova SA, Borokshinova KM, Baldueva IA, Nekhaeva TL, Artemyeva AS, Efremova NA, et al. Experience with multitargeted antitumor vaccine in a child with diffuse midline glioma, H3 K27M-mutant. Problems in Oncology. 2023;69(3):555–564. (In Russ.). https://doi.org/10.37469/0507-3758-2023-69-3-555-564Troschke-Meurer S, Zumpe M, Meißner L, Siebert N, Grabarczyk P, Forkel H, et al. Chemotherapeutics used for high-risk neuroblastoma therapy improve the efficacy of anti-GD2 antibody dinutuximab beta in preclinical spheroid models. Cancers (Basel). 2023 Jan 31;15(3):904. https://doi.org/10.3390/cancers15030904Troschke-Meurer S, Zumpe M, Meißner L, Siebert N, Grabarczyk P, Forkel H, et al. Chemotherapeutics used for high-risk neuroblastoma therapy improve the efficacy of anti-GD2 antibody dinutuximab beta in preclinical spheroid models. Cancers (Basel). 2023 Jan 31;15(3):904. https://doi.org/10.3390/cancers15030904Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol. 2020;10:1000. https://doi.org/10.3389/fonc.2020.01000Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol. 2020;10:1000. https://doi.org/10.3389/fonc.2020.01000Wingerter A, El Malki K, Sandhoff R, Seidmann L, Wagner DC, Lehmann N, et al. Exploiting gangliosides for the therapy of Ewing's sarcoma and H3K27M-mutant diffuse midline glioma. Cancers (Basel). 2021 Jan 29;13(3). https://doi.org/10.3390/cancers13030520Wingerter A, El Malki K, Sandhoff R, Seidmann L, Wagner DC, Lehmann N, et al. Exploiting gangliosides for the therapy of Ewing's sarcoma and H3K27M-mutant diffuse midline glioma. Cancers (Basel). 2021 Jan 29;13(3). https://doi.org/10.3390/cancers13030520Борокшинова К.М., Кулева С.А., Балдуева И.А. Использование вакцинного препарата на основе нового иммунологического адъюванта у пациента с диффузной срединной глиальной опухолью с мутацией H3K27M. Российский журнал детской гематологии и онкологии. 2022;(S1):34–35.Borokshinova KM, Kulyova SA, Baldueva IA. Use of a vaccine preparation based on a new immunological adjuvant in a patient with diffuse medial glial tumor with H3K27M mutation. Russian Journal of Pediatric Hematology аnd Oncology. 2022;(S1):34–35. (In Russ.).Борокшинова К.М., Кулева С.А., Балдуева И.А., Нехаева Т.Л., Новик А.В., Емельянова Н.В., и др. Результаты активной иммунотерапии у детей с солидными опухолями. Вопросы онкологии. 2023;69(3S):254–255.Borokshinova KM, Kulyova SA, Baldueva IA, Nekhaeva TL, Novik AV, Efremova NA, et al. Results of active immunotherapy in children with solid tumors. Problems in Oncology. 2023;69(3S):254–255. (In Russ.).Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: A phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2023;9(1):112–121. https://doi.org/10.1001/jamaoncol.2022.5370Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: A phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2023;9(1):112–121. https://doi.org/10.1001/jamaoncol.2022.5370Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L, et al. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurg Focus. 2000 Dec 15;9(6):e8. https://doi.org/10.3171/foc.2000.9.6.9Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L, et al. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurg Focus. 2000 Dec 15;9(6):e8. https://doi.org/10.3171/foc.2000.9.6.9Lv L, Huang J, Xi H, Zhou X. Efficacy and safety of dendritic cell vaccines for patients with glioblastoma: A meta-analysis of randomized controlled trials. Int Immunopharmacol. 2020;83:106336. https://doi.org/10.1016/j.intimp.2020.106336Lv L, Huang J, Xi H, Zhou X. Efficacy and safety of dendritic cell vaccines for patients with glioblastoma: A meta-analysis of randomized controlled trials. Int Immunopharmacol. 2020;83:106336. https://doi.org/10.1016/j.intimp.2020.106336Van Gool SW, Makalowski J, Van de Vliet P, Van Gool S., Sprenger T, Schirrmacher V, Stuecker W. Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience. Cancers (Basel). 2023;15:1194. https://doi.org/10.3390/cancers15041194Van Gool SW, Makalowski J, Van de Vliet P, Van Gool S., Sprenger T, Schirrmacher V, Stuecker W. Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience. Cancers (Basel). 2023;15:1194. https://doi.org/10.3390/cancers15041194Wang QT, Nie Y, Sun SN, Lin T, Han RJ, Jiang J, et al. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Cancer Immunol Immunother. 2020;69(7):1375–1387. https://doi.org/10.1007/s00262-020-02496-wWang QT, Nie Y, Sun SN, Lin T, Han RJ, Jiang J, et al. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Cancer Immunol Immunother. 2020;69(7):1375–1387. https://doi.org/10.1007/s00262-020-02496-wYang S, Sun Y, Liu W, Zhang Y, Sun G, Xiang B, Yang J. Exosomes in Glioma: Unraveling Their Roles in Progression, Diagnosis, and Therapy. Cancers (Basel). 2024 Feb 18;16(4):823. https://doi.org/10.3390/cancers16040823Yang S, Sun Y, Liu W, Zhang Y, Sun G, Xiang B, Yang J. Exosomes in Glioma: Unraveling Their Roles in Progression, Diagnosis, and Therapy. Cancers (Basel). 2024 Feb 18;16(4):823. https://doi.org/10.3390/cancers16040823Liu H, Chen L, Liu J, Meng H, Zhang R, Ma L, et al. Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma. Cancer Lett. 2017;411:182–190. https://doi.org/10.1016/j.canlet.2017.09.022Liu H, Chen L, Liu J, Meng H, Zhang R, Ma L, et al. Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma. Cancer Lett. 2017;411:182–190. https://doi.org/10.1016/j.canlet.2017.09.022Zhu H, Wang K, Wang Z, Wang D, Yin X, Liu Y, et al. An efficient and safe muc1-dendritic cell-derived exosome conjugate vaccine elicits potent cellular and humoral immunity and tumor inhibition in vivo. Acta Biomater. 2022;138:491–504. https://doi.org/10.1016/j.actbio.2021.10.041Zhu H, Wang K, Wang Z, Wang D, Yin X, Liu Y, et al. An efficient and safe muc1-dendritic cell-derived exosome conjugate vaccine elicits potent cellular and humoral immunity and tumor inhibition in vivo. Acta Biomater. 2022;138:491–504. https://doi.org/10.1016/j.actbio.2021.10.041Ghorbaninezhad F, Alemohammad H, Najafzadeh B, Masoumi J, Shadbad MA, Shahpouri M, et al. Dendritic cell-derived exosomes: A new horizon in personalized cancer immunotherapy? Cancer Lett. 2023;562:216168. https://doi.org/10.1016/j.canlet.2023.216168Ghorbaninezhad F, Alemohammad H, Najafzadeh B, Masoumi J, Shadbad MA, Shahpouri M, et al. Dendritic cell-derived exosomes: A new horizon in personalized cancer immunotherapy? Cancer Lett. 2023;562:216168. https://doi.org/10.1016/j.canlet.2023.216168Hao X, Wang S, Wang L, Li J, Li Y, Liu J. Exosomes as drug delivery systems in glioma immunotherapy. J Nanobiotechnology. 2024 Jun 18;22(1):340. https://doi.org/10.1186/s12951-024-02611-4Hao X, Wang S, Wang L, Li J, Li Y, Liu J. Exosomes as drug delivery systems in glioma immunotherapy. J Nanobiotechnology. 2024 Jun 18;22(1):340. https://doi.org/10.1186/s12951-024-02611-4Molenaar RJ, Maciejewski JP, Wilmink JW, van Noorden CJF. Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene. 2018 Apr;37(15):1949–1960. https://doi.org/10.1038/s41388-018-0455-1Molenaar RJ, Maciejewski JP, Wilmink JW, van Noorden CJF. Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene. 2018 Apr;37(15):1949–1960. https://doi.org/10.1038/s41388-018-0455-1Ciesielski MJ, Ahluwalia MS, Munich SA, Orton M, Barone T, Chanan-Khan A, Fenstermaker RA. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother. 2010 Aug;59(8):1211–1221. https://doi.org/10.1007/s00262-010-0845-xCiesielski MJ, Ahluwalia MS, Munich SA, Orton M, Barone T, Chanan-Khan A, Fenstermaker RA. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother. 2010 Aug;59(8):1211–1221. https://doi.org/10.1007/s00262-010-0845-xFigel S, Birkemeier M, Dharma SS, Barone T, Steinmetz E, Ciesielski M, Fenstermaker R. Wild type, dEX3 and 2B survivin isoforms localize to the tumor cell plasma membrane, are secreted in exosomes, and interact with extracellular tubulin. Biochem Biophys Rep. 2021 Nov 20;28:101174. https://doi.org/10.1016/j.bbrep.2021.101174Figel S, Birkemeier M, Dharma SS, Barone T, Steinmetz E, Ciesielski M, Fenstermaker R. Wild type, dEX3 and 2B survivin isoforms localize to the tumor cell plasma membrane, are secreted in exosomes, and interact with extracellular tubulin. Biochem Biophys Rep. 2021 Nov 20;28:101174. https://doi.org/10.1016/j.bbrep.2021.101174Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, et al. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer. 2003 Feb 15;97(4):1077–1083. https://doi.org/10.1002/cncr.11122Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, et al. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer. 2003 Feb 15;97(4):1077–1083. https://doi.org/10.1002/cncr.11122Ahluwalia MS, Reardon DA, Abad AP, Curry WT, Wong ET, Figel SA, et al. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. J Clin Oncol. 2023 Mar 1;41(7):1453–1465. https://doi.org/10.1200/JCO.22.00996Ahluwalia MS, Reardon DA, Abad AP, Curry WT, Wong ET, Figel SA, et al. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. J Clin Oncol. 2023 Mar 1;41(7):1453–1465. https://doi.org/10.1200/JCO.22.00996Sayour EJ, Boczkowski D, Mitchell DA, Nair SK. Cancer mRNA vaccines: clinical advances and future opportunities. Nat Rev Clin Oncol. 2024;21:489–500. https://doi.org/10.1038/s41571-024-00902-1Sayour EJ, Boczkowski D, Mitchell DA, Nair SK. Cancer mRNA vaccines: clinical advances and future opportunities. Nat Rev Clin Oncol. 2024;21:489–500. https://doi.org/10.1038/s41571-024-00902-1Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326–1335. https://doi.org/10.1021/acs.nanolett.6b03329Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326–1335. https://doi.org/10.1021/acs.nanolett.6b03329Sayour EJ, Grippin A, De Leon G, Stover B, Rahman M, Karachi A, et al. Personalized tumor RNA loaded lipid-nanoparticles prime the systemic and intratumoral milieu for response to cancer immunotherapy. Nano Lett. 2018 Oct 10;18(10):6195–6206. https://doi.org/10.1021/acs.nanolett.8b02179Sayour EJ, Grippin A, De Leon G, Stover B, Rahman M, Karachi A, et al. Personalized tumor RNA loaded lipid-nanoparticles prime the systemic and intratumoral milieu for response to cancer immunotherapy. Nano Lett. 2018 Oct 10;18(10):6195–6206. https://doi.org/10.1021/acs.nanolett.8b02179Dörrie J, Schaft N, Schuler G, Schuler-Thurner B. Therapeutic cancer vaccination with ex vivo RNA-transfected dendritic cells – An update. Pharmaceutics. 2020;12(2):92. https://doi.org/10.3390/pharmaceutics12020092Dörrie J, Schaft N, Schuler G, Schuler-Thurner B. Therapeutic cancer vaccination with ex vivo RNA-transfected dendritic cells – An update. Pharmaceutics. 2020;12(2):92. https://doi.org/10.3390/pharmaceutics12020092Mendez-Gomez HR, DeVries A, Castillo P, von Roemelingvon C, Qdaisat S, Stover BD, et al. RNA aggregates harness the danger response for potent cancer immunotherapy. Cell. 2024;187(10):2521–2535. https://doi.org/10.1016/j.cell.2024.04.003Mendez-Gomez HR, DeVries A, Castillo P, von Roemelingvon C, Qdaisat S, Stover BD, et al. RNA aggregates harness the danger response for potent cancer immunotherapy. Cell. 2024;187(10):2521–2535. https://doi.org/10.1016/j.cell.2024.04.003Wu J, Waxman DJ. Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy. Cancer Lett. 2018;419:210–221. https://doi.org/10.1016/j.canlet.2018.01.050Wu J, Waxman DJ. Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy. Cancer Lett. 2018;419:210–221. https://doi.org/10.1016/j.canlet.2018.01.050Zhao B, Yao L, Hatami M, Ma W, Skutella T. Vaccine-based immunotherapy and related preclinical models for glioma. Trends in Molecular Medicine. 2024;30(10):965–981. https://doi.org/10.1016/j.molmed.2024.06.009Zhao B, Yao L, Hatami M, Ma W, Skutella T. Vaccine-based immunotherapy and related preclinical models for glioma. Trends in Molecular Medicine. 2024;30(10):965–981. https://doi.org/10.1016/j.molmed.2024.06.009Tapescu I, Madsen PJ, Lowenstein PR, Castro MG, Bagley SJ, Fan Y, Brem S. The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials. Front Oncol. 2024 Sep 27;14:1454370. https://doi.org/10.3389/fonc.2024.1454370Tapescu I, Madsen PJ, Lowenstein PR, Castro MG, Bagley SJ, Fan Y, Brem S. The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials. Front Oncol. 2024 Sep 27;14:1454370. https://doi.org/10.3389/fonc.2024.1454370Hato L, Vizcay A, Eguren I, Pérez-Gracia JL, Rodríguez J, Gállego Pérez-Larraya J, et al. Dendritic cells in cancer immunology and immunotherapy. Cancers (Basel). 2024 Feb 28;16(5):981. https://doi.org/10.3390/cancers16050981Hato L, Vizcay A, Eguren I, Pérez-Gracia JL, Rodríguez J, Gállego Pérez-Larraya J, et al. Dendritic cells in cancer immunology and immunotherapy. Cancers (Basel). 2024 Feb 28;16(5):981. https://doi.org/10.3390/cancers16050981

The authors declare that there are no conflicts of interest present.